RJA
TNDM icon

Raymond James & Associates’s Tandem Diabetes Care TNDM Stock Holding History

Raymond James & Associates’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.43M Buy
104,418
+7,747
+8% +$328K ﹤0.01% 1737
2024
Q2 		$3.89M Sell
96,671
-177
-0.2% -$7.38K ﹤0.01% 1766
2024
Q1 		$3.43M Buy
96,848
+4,863
+5% +$130K ﹤0.01% 1826
2023
Q4 		$2.72M Buy
91,985
+51,721
+128% +$1.07M ﹤0.01% 1908
2023
Q3 		$836K Buy
40,264
+737
+2% +$20.2K ﹤0.01% 2581
2023
Q2 		$970K Buy
39,527
+3,338
+9% +$107K ﹤0.01% 2493
2023
Q1 		$1.47M Buy
36,189
+5,236
+17% +$217K ﹤0.01% 2216
2022
Q4 		$1.39M Buy
30,953
+7,840
+34% +$355K ﹤0.01% 2230
2022
Q3 		$1.11M Buy
23,113
+4,935
+27% +$271K ﹤0.01% 2333
2022
Q2 		$1.08M Buy
18,178
+1,879
+12% +$154K ﹤0.01% 2385
2022
Q1 		$1.9M Sell
16,299
-5,393
-25% -$630K ﹤0.01% 2166
2021
Q4 		$3.27M Buy
21,692
+4,097
+23% +$553K ﹤0.01% 1830
2021
Q3 		$2.1M Sell
17,595
-1,152
-6% -$127K ﹤0.01% 2064
2021
Q2 		$1.83M Buy
18,747
+1,366
+8% +$122K ﹤0.01% 2162
2021
Q1 		$1.53M Sell
17,381
-5,447
-24% -$506K ﹤0.01% 2203
2020
Q4 		$2.18M Sell
22,828
-39,710
-63% -$4.09M ﹤0.01% 1835
2020
Q3 		$7.1M Buy
62,538
+17,515
+39% +$1.84M 0.01% 1035
2020
Q2 		$4.45M Buy
45,023
+3,609
+9% +$288K 0.01% 1258
2020
Q1 		$2.67M Sell
41,414
-222
-0.5% -$15.6K ﹤0.01% 1415
2019
Q4 		$2.48M Sell
41,636
-69,987
-63% -$4.32M ﹤0.01% 1696
2019
Q3 		$6.58M Buy
111,623
+2,409
+2% +$154K 0.01% 1071
2019
Q2 		$7.05M Buy
109,214
+88,532
+428% +$5.71M 0.01% 1042
2019
Q1 		$1.31M Buy
20,682
+3,605
+21% +$189K ﹤0.01% 2039
2018
Q4 		$648K Buy
17,077
+10,075
+144% +$356K ﹤0.01% 2367
2018
Q3 		$300K Buy
+7,002
New +$245K ﹤0.01% 3029
2017
Q4 		– Sell
-1,500
Closed -$11K – 3524
2017
Q3 		$11K Hold
1,500
– – ﹤0.01% 3346
2017
Q2 		$12K Buy
+1,500
New +$13.9K ﹤0.01% 3287

Other funds holding TNDM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's TNDM Position: Q3 2024 in Review

Raymond James & Associates increased its Tandem Diabetes Care (TNDM) stake by 8% in Q3 2024, buying an estimated $328K and bringing the position to 104,418 shares worth $4.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1737.

Raymond James & Associates first reported a position in TNDM in Q2 2017 and has held it in 27 quarters since. The position peaked at $7.1M in Q3 2020. 332 funds tracked by Wall St. Rank hold TNDM as of Q3 2024.

  • Raymond James & Associates held 104,418 shares of Tandem Diabetes Care worth $4.43M as of Q3 2024.
  • Raymond James & Associates bought 7,747 Tandem Diabetes Care shares in Q3 2024, an estimated $328K.
  • Tandem Diabetes Care made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1737 holding.
  • Raymond James & Associates first reported a position in Tandem Diabetes Care in Q2 2017 and has held it in 27 quarters since.
  • Raymond James & Associates's Tandem Diabetes Care position peaked at $7.1M in Q3 2020.
  • 332 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.